Aytu BioScience Inc Asset Resilience Ratio
Aytu BioScience Inc asset resilience ratio. Aytu BioScience Inc (AYTU) has an Asset Resilience Ratio of 0.56% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Aytu BioScience Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Aytu BioScience Inc (2016–2018)
Asset resilience ratio of Aytu BioScience Inc from 2016 to 2018. This chart shows how Aytu BioScience Inc's Asset Resilience Ratio has changed over time. Read AYTU total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Aytu BioScience Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Aytu BioScience Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $100.00K | 0.56% |
| Total Liquid Assets | $100.00K | 0.56% |
Asset Resilience Insights
- Limited Liquidity: Aytu BioScience Inc maintains only 0.56% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Aytu BioScience Inc Industry Peers by Asset Resilience Ratio
Compare Aytu BioScience Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Aytu BioScience Inc Asset Resilience Ratio by Year (2016–2018)
Aytu BioScience Inc asset resilience ratio by year from 2016 to 2018. The table below shows the annual Asset Resilience Ratio data for Aytu BioScience Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-06-30 | 0.47% | $100.00K | $21.06 Million | -- |
| 2017-06-30 | 0.00% | $0.00 | $15.00 Million | -- |
| 2016-06-30 | 4.28% | $1.04 Million | $24.34 Million | -- |
About Aytu BioScience Inc
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release o… Read more